-
公开(公告)号：US20160046707A1
公开(公告)日：2016-02-18
申请号：US14816989
申请日：2015-08-03
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Abstract translation: 本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。 本发明还涉及所述抗体的重链和轻链。 本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。 本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。
-
公开(公告)号：US09133273B2
公开(公告)日：2015-09-15
申请号：US13924433
申请日：2013-06-21
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Abstract translation: 本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。 本发明还涉及所述抗体的重链和轻链。 本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。 本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。
-
公开(公告)号：US09809647B2
公开(公告)日：2017-11-07
申请号：US14816989
申请日：2015-08-03
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
-
-
Search Results
3
records
(took 0.019 seconds)
